Remedy Plan Therapeutics
- Biotech or pharma, therapeutic R&D
Remedy Plan Therapeutics is a privately held, clinical-stage pharmaceutical company transforming the field of NAMPT inhibition, with a pipeline of novel, hyperbolic NAMPT inhibitors. Remedy Plan's novel NAMPT inhibitors have broad therapeutic applications in cancer, autoimmune, and metabolic diseases. Our lead asset RPT1G is currently in a Phase 1 trial in healthy volunteers and will be advancing into oncology later this year. We are exploring future lead investors and strategic partners.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}